Evidence map›Paper›PMID 40132186›Full record

ArticleJournal of medical Internet research2025

Consumer Engagement With Risk Information on Prescription Drug Social Media Pages: Findings From In-Depth Interviews.

Jacqueline B Amoozegar, Peyton Williams, Kristen C Giombi, Courtney Richardson, Ella Shenkar, Rebecca L Watkins, Amie C O'Donoghue, Helen W Sullivan

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jacqueline B AmoozegarRTI International, Research Triangle Park, NC, United States.ORCID https://orcid.org/0000-0003-2415-8358
Peyton WilliamsRTI International, Research Triangle Park, NC, United States.ORCID https://orcid.org/0000-0002-7167-9116
Kristen C GiombiRTI International, Research Triangle Park, NC, United States.ORCID https://orcid.org/0000-0002-8788-0391
Courtney RichardsonRTI International, Research Triangle Park, NC, United States.ORCID https://orcid.org/0000-0002-3508-3956
Ella ShenkarRTI International, Research Triangle Park, NC, United States.ORCID https://orcid.org/0009-0006-9490-0174
Rebecca L WatkinsRTI International, Research Triangle Park, NC, United States.ORCID https://orcid.org/0000-0002-9573-7800
Amie C O'DonoghueUS Food and Drug Administration, Silver Spring, MD, United States.ORCID https://orcid.org/0000-0003-0882-2845
Helen W SullivanUS Food and Drug Administration, Silver Spring, MD, United States.ORCID https://orcid.org/0000-0001-7621-7554

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe volume of digital drug promotion has grown over time, and social media has become a source of information about prescription drugs for many consumers. Pharmaceutical companies currently present risk information about prescription drugs they promote in a variety of ways within and across social media platforms. There is scarce research on consumers' interactions with prescription drug promotion on social media, particularly on which features may facilitate or inhibit consumers' ability to find, review, and comprehend drug information. This is concerning because it is critical for consumers to know and weigh drug benefits and risks to be able to make informed decisions regarding medical treatment.

objectiveWe aimed to develop an understanding of the user interface (UI) and user experience (UX) of social media pages and posts created by pharmaceutical companies to promote drugs and how UI or UX design features impact consumers' interactions with drug information.

methodsWe conducted in-person interviews with 54 consumers segmented into groups by device type (laptop or mobile phone), social media platform (Facebook or Instagram), and age. Interviewers asked participants to navigate to and review a series of 4 pages and 3 posts on their assigned device and platform. Interviewers encouraged participants to "think aloud," as they interacted with the stimuli during a brief observation period. Following each observation period, participants were asked probing questions. An analyst reviewed video recordings of the observation periods to abstract quantitative interaction data on whether a participant clicked on or viewed risk information at each location it appeared on each page. Participants' responses were organized in a metamatrix, which we used to conduct thematic analysis.

resultsObservational data revealed that 59% of participants using Facebook and 70% of participants using Instagram viewed risk information in at least 1 possible location on average across all pages tested during the observation period. There was not a single location across the Facebook pages that participants commonly clicked on to view risk information. However, a video with scrolling risk information attracted more views than other features. On Instagram, at least half of the participants consistently clicked on the highlighted story with risk information across the pages. Although thematic analysis showed that most participants were able to identify the official pages and risk information for each drug, auto-scrolling text and text size posed barriers to identification and comprehensive review for some participants. Participants generally found it more difficult to identify the drugs' indications than risks. Participants using Instagram more frequently reported challenges identifying risks and indications compared to those using Facebook.

conclusionsUI or UX design features can facilitate or pose barriers to users' identification, review, and comprehension of the risk information provided on prescription drugs' social media pages and posts.

Indexed as

Prescription DrugsSocial MediaAdultAgedFemaleHumansInterviews as TopicMaleMiddle AgedYoung AdultPrescription Drugsconsumer engagementdigitaldrug promotionFacebookinformationInstagraminterviewprescriptionprescription drugspromotionriskrisk informationsafetysafety informationsocial mediauser experience

Identifiers

PMID40132186
PMCPMC11979525

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.